...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Primary Endpoint Results for Phase 3 BETonMACE Cardio Outcomes Trial were Announced September 30th ****Detailed Trial Data to be Presented at AHA Late Breaking Session Nov 16th & Company Webcast Nov 18th******

Message: Vacepa new

It looks like this fish oil drug is working wonders for those taking it. (I started on it about two months ago and it cut my tryglicirides by 40% but it’s ultra expensive stuff.

Is this a boon or a bane or just not relevant for our BETOnMACE project that we are expecting to hear more about by July ‘19 (or later)

In the meantime not much to expect, except our long awaited wait for the promised additional funding discussed at the end of January.

Comments? (Up to $19 per share on the Vascepa parent)

New Message
Please login to post a reply